Merck & Company (MRK) 56.35 $MRK
Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
Business Wire - 14 mins ago
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).
Is Now a Good Time to Buy Bristol Myers?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 45 mins ago
Bristol-Myers updated investors on its prolific research program for the cancer drug nivolumab this week. The news came in a flurry Wednesday, beginning with a new combination study planned with Celldex , and culminating with updated data for...
Global Life Science Reagents Market - Forecasts to 2019: Key players profiled in this report include Abbott, Agilent, Lonza, Promega, Sigma Aldrich, Merck Millipore, Siemens and Bio-Rad
PR Newswire - Mon May 19, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j9nj58/life_science) has announced the addition of the "Global Life Science Reagents Market - Forecasts to 2019: Key players profiled in this report include Abbott, Agilent, Lonza, Promega, Sigma Aldrich, Merck Millipore, Siemens and Bio-Rad" report to their offering.
Interesting August Stock Options For MRK
at The Street - Mon May 19, 11:38AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co. .
Wellframe Continues to Gain Momentum and is Named Winner of Merck | Heritage Provider Network Innovation Challenge
PRWeb - Mon May 19, 11:31AM CDT
Wellframe, a Boston-based company that combines mobile technology and artificial intelligence to amplify caring clinical relationships by engaging patients in personalized care plans, today announced that the organization has been named winner of the Merck | Heritage Provider Network Innovation Challenge. This award closely follows the dual announcements that the Wellframe had secured $1.5 million in seed funding this past April, and that the first commercial rollout of the Wellframe solution was completed in February.
The Dow Hangs Tough as Pfizer, Merck Offset Telecom Weakness
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 19, 10:02AM CDT
On Monday morning, the Dow Jones Industrials stayed within a narrow range, initially losing about 50 points but clawing back most of that loss within the first hour of the trading day. As of 11 a.m. EDT, the Dow was down just eight points....
Merck Earnings Review: 20 Days after Announcement Shares Down 4.9% (MRK)
Comtex SmarTrend(R) - Mon May 19, 8:50AM CDT
20 days ago, on April 29th, 2014, Merck (NYSE:MRK) reported its earnings. Analysts, on average, expected earnings of $0.79 per share on sales of $10.4 billion. The company actually reported EPS of $0.88 on sales of $10.3 billion, beating EPS estimates by $0.09 and missing revenue estimates by $179.7 million. Since the company's report, shares of Merck have fallen from $58.72 to $55.87, representing a loss of 4.9% in the past 20 days.
Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 5:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.
Parkinson's Disease Sinemet by Merck & Co - Forecast and Market Analysis to 2022
M2 - Mon May 19, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9sqjd9/sinemet) has announced the addition of the "Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Sinemet (carbidopa and levodopa), developed by Merck & Co., is considered one of the gold standards for treatment in Parkinson's disease. It is used for the control of motor symptoms in Parkinson's disease and other Parkinsonian syndromes. Sinemet does not slow the neurodegenerative process in Parkinson's disease, and over time patients' responsiveness to therapy may change as they enter more advanced stages of the disease. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Sinemet performance - Obtain sales forecast for Sinemet from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Sinemet (carbidopa/levodopa) 7 Appendix For more information visit http://www.researchandmarkets.com/research/9sqjd9/sinemet
PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5dnt/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. The aging population in Japan is growing at an accelerated rate compared with other countries forecast in this report, accounting for the significant hike in sales during the 10-year forecast, along with low rates of generic substitution. Several products will be launched between 2012 and 2016, with some losing patent life during the same forecast period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management - Diagnosis - The UK Brain Bank Criteria - Treatment Guidelines and Leading Prescribed Drugs - Dopaminergic Therapy Classes - Treatment of Parkinson's disease by Stage - Parkinson's Disease Assessment Scales - Unified Parkinson's Disease Rating Scale (UPDRS) - Hoehn and Yahr Clinical Staging - Other Clinical Assessments 5 Competitive Assessment - Product Profiles - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Product Profiles - Adenosine 2A Inhibitor - Product Profiles - Other Therapies 6 Opportunity and Unmet Need - Treatment of Motor Complications - Dyskinesias and OFF Episodes - Treatment of Non-Motor Symptoms and Dementia - Neuroprotective/Disease-Modifying Agents - Improved Drug Formulations - Identification of Reliable Biomarkers - Improved Clinical Trial Design 7 Pipeline Assessment - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/6w...harmapoint
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v2dlk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug. Scope - Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Safinamide for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Safinamide 9 Appendix For more information visit http://www.researchandmarkets.com/research/3v2dlk/safinamide
Pfizer raises offer, highlighting flurry of deals
By The Associated Press - AP - Mon May 19, 3:25AM CDT
U.S. drugmaker Pfizer has raised its takeover bid for British rival AstraZeneca for a third time, hiking the stock-and-cash offer to nearly $119 billion (70.7 billion pounds), but AstraZeneca has quickly rejected it. The move is the latest in a flurry of proposed drug takeovers this year. The deals highlight how the global pharmaceutical industry could over time consolidate into a very small number of massive companies as competition increases from generic versions of medicines. The enhanced economies of scale could boost returns for shareholders but what it means for consumers is still unclear.
The Dow's Dividend Giants: Yield Isn't Everything
Dan Caplinger, The Motley Fool - Motley Fool - Sun May 18, 8:05AM CDT
Dividends are important, and one of the best things about the Dow Jones Industrials is that every one of the 30 component stocks that make up the Dow pay a dividend. But when it comes to dividends, it is possible to have too much of a good thing...
The Hidden Link Between Obesity and Marijuana
George Budwell, The Motley Fool - Motley Fool - Sun May 18, 7:03AM CDT
Marijuana's uncanny ability to make us feel hungry has long intrigued the medical community. Currently, many states allow marijuana to be prescribed for its therapeutic benefits, especially for patients who have trouble drumming up an appetite. The...
Could a Vaccine-Based Cancer Cure Be Around the Corner?
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:40PM CDT
Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on. Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon...
ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies...
Merck & Co. Inc. Pays Out All of Its Profits as Dividends. Is This Generous Policy Doomed to Collaps
Anders Bylund, The Motley Fool - Motley Fool - Fri May 16, 1:00PM CDT
In some ways, Merck is the most generous dividend payer on the Dow Jones Industrial Average . That's obviously great for Merck investors -- unless the pharma giant is going too far, of course. Is Merck simply serving shareholders to the best...
Brazil Parkinson's Disease Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xcc66k/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022" report to their offering. The decline in sales is attributed to a private-public partnership (PPP) between Brazil and Boehringer Ingelheim, which will drive down the price of generic pramipexole as the technology to produce the drug is transferred to Brazil's Oswaldo Cruz Foundation (Fiocruz)/Institute of Drug Technology (Farmanguinhos), which will solely be responsible for the country's production of the drug by 2017. Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Brazil from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the Brazil Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Current and Future Players 9 Market Outlook 10 Appendix Companies Mentioned - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck For more information visit http://www.researchandmarkets.com/research/xc...harmapoint
US Parkinson's Disease Report 2014 - Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7wtll/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - US Drug Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period. This market is expected to grow faster than any other market, including the 5EU, due in part to the introduction of two brands already in use in the 5EU, Neupro and Duodopa, launched in the US at the beginning of the forecast in 2012 and 2014, respectively. Other factors responsible for growth in this market are an aging population that contributes to an increased prevalence of Parkinson's disease in the US and the launch of six new pipeline agents (in addition to Duodopa and Neupro). Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Requip/Requip XL (ropinirole) - Product Profiles - MAO-B Inhibitors - Product Profiles - Adenosine 2A Inhibitor 6 Opportunity and Unmet Need 7 Pipeline Assessment - Safinamide - Tozadenant - CVT-301 - Rytary/IPX066 - Opicapone - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/w7...harmapoint
Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
Business Wire - 14 mins ago
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).
Is Now a Good Time to Buy Bristol Myers?
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 45 mins ago
Bristol-Myers updated investors on its prolific research program for the cancer drug nivolumab this week. The news came in a flurry Wednesday, beginning with a new combination study planned with Celldex , and culminating with updated data for...
Global Life Science Reagents Market - Forecasts to 2019: Key players profiled in this report include Abbott, Agilent, Lonza, Promega, Sigma Aldrich, Merck Millipore, Siemens and Bio-Rad
PR Newswire - Mon May 19, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j9nj58/life_science) has announced the addition of the "Global Life Science Reagents Market - Forecasts to 2019: Key players profiled in this report include Abbott, Agilent, Lonza, Promega, Sigma Aldrich, Merck Millipore, Siemens and Bio-Rad" report to their offering.
Interesting August Stock Options For MRK
at The Street - Mon May 19, 11:38AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co. .
Wellframe Continues to Gain Momentum and is Named Winner of Merck | Heritage Provider Network Innovation Challenge
PRWeb - Mon May 19, 11:31AM CDT
Wellframe, a Boston-based company that combines mobile technology and artificial intelligence to amplify caring clinical relationships by engaging patients in personalized care plans, today announced that the organization has been named winner of the Merck | Heritage Provider Network Innovation Challenge. This award closely follows the dual announcements that the Wellframe had secured $1.5 million in seed funding this past April, and that the first commercial rollout of the Wellframe solution was completed in February.
The Dow Hangs Tough as Pfizer, Merck Offset Telecom Weakness
Dan Caplinger, The Motley Fool - Motley Fool - Mon May 19, 10:02AM CDT
On Monday morning, the Dow Jones Industrials stayed within a narrow range, initially losing about 50 points but clawing back most of that loss within the first hour of the trading day. As of 11 a.m. EDT, the Dow was down just eight points....
Merck Earnings Review: 20 Days after Announcement Shares Down 4.9% (MRK)
Comtex SmarTrend(R) - Mon May 19, 8:50AM CDT
20 days ago, on April 29th, 2014, Merck (NYSE:MRK) reported its earnings. Analysts, on average, expected earnings of $0.79 per share on sales of $10.4 billion. The company actually reported EPS of $0.88 on sales of $10.3 billion, beating EPS estimates by $0.09 and missing revenue estimates by $179.7 million. Since the company's report, shares of Merck have fallen from $58.72 to $55.87, representing a loss of 4.9% in the past 20 days.
Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 5:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.
Parkinson's Disease Sinemet by Merck & Co - Forecast and Market Analysis to 2022
M2 - Mon May 19, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9sqjd9/sinemet) has announced the addition of the "Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Sinemet (carbidopa and levodopa), developed by Merck & Co., is considered one of the gold standards for treatment in Parkinson's disease. It is used for the control of motor symptoms in Parkinson's disease and other Parkinsonian syndromes. Sinemet does not slow the neurodegenerative process in Parkinson's disease, and over time patients' responsiveness to therapy may change as they enter more advanced stages of the disease. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Sinemet performance - Obtain sales forecast for Sinemet from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Sinemet (carbidopa/levodopa) 7 Appendix For more information visit http://www.researchandmarkets.com/research/9sqjd9/sinemet
PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5dnt/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Japan Drug Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. The aging population in Japan is growing at an accelerated rate compared with other countries forecast in this report, accounting for the significant hike in sales during the 10-year forecast, along with low rates of generic substitution. Several products will be launched between 2012 and 2016, with some losing patent life during the same forecast period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management - Diagnosis - The UK Brain Bank Criteria - Treatment Guidelines and Leading Prescribed Drugs - Dopaminergic Therapy Classes - Treatment of Parkinson's disease by Stage - Parkinson's Disease Assessment Scales - Unified Parkinson's Disease Rating Scale (UPDRS) - Hoehn and Yahr Clinical Staging - Other Clinical Assessments 5 Competitive Assessment - Product Profiles - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Product Profiles - Adenosine 2A Inhibitor - Product Profiles - Other Therapies 6 Opportunity and Unmet Need - Treatment of Motor Complications - Dyskinesias and OFF Episodes - Treatment of Non-Motor Symptoms and Dementia - Neuroprotective/Disease-Modifying Agents - Improved Drug Formulations - Identification of Reliable Biomarkers - Improved Clinical Trial Design 7 Pipeline Assessment - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/6w...harmapoint
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v2dlk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug. Scope - Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Safinamide for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Safinamide 9 Appendix For more information visit http://www.researchandmarkets.com/research/3v2dlk/safinamide
Pfizer raises offer, highlighting flurry of deals
By The Associated Press - AP - Mon May 19, 3:25AM CDT
U.S. drugmaker Pfizer has raised its takeover bid for British rival AstraZeneca for a third time, hiking the stock-and-cash offer to nearly $119 billion (70.7 billion pounds), but AstraZeneca has quickly rejected it. The move is the latest in a flurry of proposed drug takeovers this year. The deals highlight how the global pharmaceutical industry could over time consolidate into a very small number of massive companies as competition increases from generic versions of medicines. The enhanced economies of scale could boost returns for shareholders but what it means for consumers is still unclear.
The Dow's Dividend Giants: Yield Isn't Everything
Dan Caplinger, The Motley Fool - Motley Fool - Sun May 18, 8:05AM CDT
Dividends are important, and one of the best things about the Dow Jones Industrials is that every one of the 30 component stocks that make up the Dow pay a dividend. But when it comes to dividends, it is possible to have too much of a good thing...
The Hidden Link Between Obesity and Marijuana
George Budwell, The Motley Fool - Motley Fool - Sun May 18, 7:03AM CDT
Marijuana's uncanny ability to make us feel hungry has long intrigued the medical community. Currently, many states allow marijuana to be prescribed for its therapeutic benefits, especially for patients who have trouble drumming up an appetite. The...
Could a Vaccine-Based Cancer Cure Be Around the Corner?
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:40PM CDT
Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on. Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon...
ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies...
Merck & Co. Inc. Pays Out All of Its Profits as Dividends. Is This Generous Policy Doomed to Collaps
Anders Bylund, The Motley Fool - Motley Fool - Fri May 16, 1:00PM CDT
In some ways, Merck is the most generous dividend payer on the Dow Jones Industrial Average . That's obviously great for Merck investors -- unless the pharma giant is going too far, of course. Is Merck simply serving shareholders to the best...
Brazil Parkinson's Disease Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xcc66k/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022" report to their offering. The decline in sales is attributed to a private-public partnership (PPP) between Brazil and Boehringer Ingelheim, which will drive down the price of generic pramipexole as the technology to produce the drug is transferred to Brazil's Oswaldo Cruz Foundation (Fiocruz)/Institute of Drug Technology (Farmanguinhos), which will solely be responsible for the country's production of the drug by 2017. Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Brazil from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the Brazil Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Current and Future Players 9 Market Outlook 10 Appendix Companies Mentioned - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck For more information visit http://www.researchandmarkets.com/research/xc...harmapoint
US Parkinson's Disease Report 2014 - Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7wtll/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - US Drug Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period. This market is expected to grow faster than any other market, including the 5EU, due in part to the introduction of two brands already in use in the 5EU, Neupro and Duodopa, launched in the US at the beginning of the forecast in 2012 and 2014, respectively. Other factors responsible for growth in this market are an aging population that contributes to an increased prevalence of Parkinson's disease in the US and the launch of six new pipeline agents (in addition to Duodopa and Neupro). Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Requip/Requip XL (ropinirole) - Product Profiles - MAO-B Inhibitors - Product Profiles - Adenosine 2A Inhibitor 6 Opportunity and Unmet Need 7 Pipeline Assessment - Safinamide - Tozadenant - CVT-301 - Rytary/IPX066 - Opicapone - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/w7...harmapoint
